FormsNet3 Monthly Maintenance Items

Updates to validations, question enabling/disabling and form generation occur on a monthly basis and are tentatively scheduled for the 4th Friday of the month.

January 2026 (Released January 23, 2026)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2451 R3	Q4-13	Validation (Add)	Overrides are allowed on Q4-13	Overrides are NOT allowed on Q4-13	Improved data quality. If no donor cells are found in a chimerism study, 0% must be entered in the grid, rather than leaving these fields blank
F2400 R11 & F2000 R6		Validation (Modify)	If F2400: Sequence Number: is not answered, then Q80 Dosing weight: must be answered If F2400: Sequence Number: is answered and Q39 Was a pre-HCT preparative regimen given = Yes, then Q80 Dosing weight: must be answered If F2400: Sequence Number: is not answered, then Dosing weight uom must be answered If F2400: Sequence Number: is answered and Q39 Was a pre-HCT preparative regimen given = yes, then Dosing weight uom must be answered	If Q39 Was a pre-HCT preparative regimen given = yes, then Q80 Dosing weight: must be answered If Q39 Was a pre-HCT preparative regimen given = yes, then Dosing weight uom must be answered Removed these validations: If F2400: Sequence Number: is not answered, then Q80 Dosing weight: must be answered If F2400: Sequence Number: is not answered, then Dosing weight uom must be answered	Dosing weight will be disabled on F2400 R11 and enabled on F2000 R6, where it will be collected for each drug. This change will improve the accuracy of dosing weight data.
F2057 R1	Q11, Q29, Q35	Validation (Modify)	Several validations reference the diagnosis date as the date the diagnostic labs were drawn	References to the diagnostic date have been removed from validations for diagnostic lab draw dates. Validations now require that the lab draw date be before the systemic treatment start date, aligning with validations on similar forms. Previous validations have been removed and replaced with the following: Q11 Date CBC with differential drawn: must be less than Q184 Date started. Q29 Date sample collected: must be less than Q184 Date started. Q35 Date sample collected: must be less than Q184 Date started.	Diagnostic labs must be drawn before the start of systemic treatment, but they may occur either before or after the diagnosis date
F2199 R2	Q1	Validation (Modify)	Override is allowed on Q1 Donor ID	Override is NOT allowed on Q1 Donor ID	Donor information is required for proper analysis of allo boost information

December 2025 (Released December 12th, 2025)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2400 R11	Q178	Validation (Modify)	Q178 “Specify if the recipient received any of the following” must be answered	If research is consent is equal to “Y, WAIVER, PND_AOM_Y,” then Q178 “Specify if the recipient received any of the following” must be answered	Question should only be answered for recipients providing appropriate consent
F2199 R2	Q138	Validation (Modify)	If Q6 “What is the primary indication?” is equal to “Insufficient hematopoietic recovery/graft failure,” then Q38 “What was the best response to the DCI?” must be be equal to “NR, NORM_BC, PART_NORM_BC” If Q6 “What is the primary indication? is equal to “gvhd_treatmnt, immune_reconst, infect_trtmt, INS_RECOV_GF, subopt_dnr_chim, REL_PROG_TRTMT, MRD_TRTMT,” then Q38 “What was the best response to DCI?” must be answered	If Q6 “What is the primary indication?” is equal to “Insufficient hematopoietic recovery/graft failure” or is not answered, then Q38 “What was the best response to the DCI?” must be be equal to “NR, NORM_BC, PART_NORM_BC” If Q6 “What is the primary indication? is equal to “gvhd_treatmnt, immune_reconst, infect_trtmt, INS_RECOV_GF, subopt_dnr_chim, REL_PROG_TRTMT, MRD_TRTMT” or is not answered, then Q38 “What was the best response to DCI?” must be answered	Best response will be collected for allo boosts when Q6 is not answered
	Q6	Validation (Modify)	If Q6 “What is the primary indication?” is equal to “MRD_TRTMT, REL_PROG_TRTMT,” then Q8 “Was therapy to treat disease given prior to the DCI?” must be answered	If Q6 “What is the primary indication?” is equal to “MRD_TRTMT, REL_PROG_TRTMT” or is not answered, then Q8 “Was therapy to treat disease given prior to the DCI?” must be answered	Question should be enabled for allo boosts
F2015 R3	Q7-14, 19-20, 32-48, 71-87	Validation (Modify)	Q7-14, 19-20, 32-48, 71-87 are enabled	Q7-14, 19-20, 32-48, 71-87 should be disabled when F2402 R10 is revision of F2402 that is completed	CBC and cytogenetics are collected on F2402 R10 and no longer need to be collected on F2015

November 2025 (Released November 21st, 2025)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2138 r2	Q20-22	Floating Text (Add)		Q20-22 will be leveled out, no longer child questions of Q11	To clearly show the intent is to capture testing done on a serum sample, not a CSF sample
F2402 r10	Q377	Validation (Modify)	IF AND ONLY IF Q376 disease status = Hematologic improvement, then Q377 Specify cell lines examined to determine HI status must be answered	Q377 should not be answered if the disease subtype in Q309 is JMML	Q377 is not applicable to JMML (Juvenile Myelomonocytic Leukemia)
F2157 r1	Q128	Validation (Add)		Q128 must not be equal to “not applicable”	If all molecular markers tested are negative, then the parent question (Q117) should be answered as “No”, thus skipping Q128.
F2034 r3	Q3 & Q114	Validation (Modify)	IF AND ONLY IF Is this the report of a second or subsequent transplant for the same disease? IS EQUAL TO No THEN Q3 What was the date of diagnosis? MUST BE ANSWERED. Q114 Serum ferritin MUST BE ANSWERED	IF AND ONLY IF Is this the report of a second or subsequent transplant for the same disease? IS EQUAL TO No AND Date Received: IS LESS THAN OR EQUAL TO 2025-11-21 THEN Q3 What was the date of diagnosis? MUST BE ANSWERED. (Disable Q3) ​IF AND ONLY IF Date Received: IS LESS THAN OR EQUAL TO 2025-11-21 THEN Q114 Serum ferritin MUST BE ANSWERED. (Disable Q114)	Disabling Q3 because it is a duplicate, this question is captured on F2402. Disabling Q114 (and child questions 115-116) because they are duplicates. These questions are captured on F2400
F2056 r1	Q5	Validation (Modify)	IF AND ONLY IF Is this the report of a second or subsequent transplant for the same disease? = No, THEN Q5 MUST BE ANSWERED.	IF AND ONLY IF Is this the report of a second or subsequent transplant for the same disease? IS EQUAL TO No AND Date Received: IS LESS THAN OR EQUAL TO 2025-11-21 THEN (5) What was the date of diagnosis? MUST BE ANSWERED. (Disable Q5)	Disabling Q5 because it is a duplicate, this question is captured on F2402.
F2039 r3	Q3	Validation (Modify)	IF AND ONLY IF Is this the report of a second or subsequent transplant for the same disease? = No, THEN Q3 MUST BE ANSWERED.	IF AND ONLY IF Is this the report of a second or subsequent transplant for the same disease? IS EQUAL TO No AND Date Received: IS LESS THAN OR EQUAL TO 2025-11-21 THEN Q3 What was the date of diagnosis? MUST BE ANSWERED. (Disable Q3)	Disabling Q3 because it is a duplicate. This question is capture on F2402
F2019 r3	Q151	Validation (Modify)	Q151 What was the disease status at the last evaluation prior to the preparative regimen? MUST BE ANSWERED	IF AND ONLY IF Received Date: IS LESS THAN OR EQUAL TO 2025-11-21 THEN Q151 What was the disease status at the last evaluation prior to the preparative regimen? MUST BE ANSWERED. (Disable Q151)	Disabling Q151 because it is a duplicate. This question is capture on F2402

October 2025 (Released October 24th, 2025)

Form Revision	Question	Type of Change	Current	New	Rationale for Change
2030 r5	Q39	Validation (Modify)	Q39 Cystatin-C must be answered	Q39 will be disabled	Questions will be disabled as F2400 r11 now captures information
2000 r6	Q39	Validation (Modify)	If and only if Q39 “Was a pre-HCT preparative regimen given?” is equal to “yes,” then Q80 “dosing weight” must be answered	If and only if Q39 “Was a pre-HCT preparative regimen given?” is equal to “yes” and if date received is less than or equal to 2025-10-24, then Q80 “dosing weight” must be answered
	Q104		Q104 “Is the recipient an adult (18 years of age or older) or emancipated minor?” must be answered	If date received is less than or equal to 2025-10-24, then Q104 “Is the recipient an adult (18 years of age or older) or emancipated minor?” must be answered
	Q109		Q109 “What is the highest educational grade the recipient completed?” must be answered	If date received is less than or equal to 2025-10-24, then Q109 “What is the highest educational grade the recipient completed?” must be answered
	Q111		Q111 “Is the recipient covered by health insurance?” must be answered	If date received is less than or equal to 2025-10-24, then Q111 “Is the recipient covered by health insurance?” must be answered
4000 r10	Q1 & Q2	Validation (Modify)	If international center, then Q1 “Ethnicity” and Q2 “Race” are optional If US center, then Q1 “Ethnicity” and Q2 “Race” must be answered	If international center and date received is less than or equal to 2025-10-24, then Q1 “Ethnicity” and Q2 “Race” are optional If US center and date received is less than or equal to 2025-10-24, then Q1 “Ethnicity” and Q2 “Race” are required	Q1 & Q2 will be disabled as F2807 r1 collects information and is required for both international and US centers
2010 r4	Q10	Validation (Modify)	If and only if “Is this the report of a second or subsequent transplant or cellular therapy for the same disease?” is “no,” then Q10 “Did the recipient have a documented antecedent hematologic disorder?” must be answered	If and only if “Is this the report of a second or subsequent transplant or cellular therapy for the same disease?” is “no” and date received is less than or equal to 2025-10-24, then Q10 “Did the recipient have a documented antecedent hematologic disorder?” must be answered	Q10-Q13 will be disabled as F2402 r10 now collects information
2014 r4	Q40 & Q177	Validation (Modify)	If and only if Q1 “Is this the report of a second or subsequent transplant or cellular therapy for the same disease?” is “no,” then Q40 “Were molecular tests for molecular markers performed?” must be answered If and only if “infusion primary disease” is equal to MDS, then Q177 “Were molecular tests for molecular markers performed?” must be answered	If and only if Q1 “Is this the report of a second or subsequent transplant or cellular therapy for the same disease?” is “no” and date received is less than or equal to 2025-10-24, then Q40 “Were molecular tests for molecular markers performed?” must be answered If and only if “infusion primary disease” is equal to MDS and date received is less than or equal to 2025-10-24, then Q177 “Were molecular tests for molecular markers performed?” must be answered If “primary disease” is AML and date received is greater than or equal to 2025-10-24, then Q177 “Were molecular tests for molecular markers performed?” must be answered	Q40-Q47 and Q177-Q184 will be disabled as molecular markers at diagnosis and last evaluation are now collected on F2402 r10 when primary disease is MDS Molecular markers at last evaluation will still be collected on F2014 when the primary disease on F2402 is AML but a transformation has been reported
2057 r1	Q33 & Q233	Validation (Modify)	If and only if Q1 “Is this the report of a second or subsequent transplant or cellular therapy for the same disease?” is equal to “no,” then Q33 “Were molecular tests for molecular markers performed?” must be answered If and only if “Infusion primary disease” is equal to “MPN,” then Q233 “ Were molecular tests for molecular markers performed?” must be answered	If and only if Q1 “Is this the report of a second or subsequent transplant or cellular therapy for the same disease?” is equal to “no” and date received is less than or equal to 2025-10-24, then Q33 “Were molecular tests for molecular markers performed?” must be answered If and only if “Infusion primary disease” is equal to “MPN” and date received is less than or equal to 2025-10-24, then Q233 “Were molecular tests for molecular markers performed?” must be answered If and only if “Infusion primary disease” is equal to “AML” and if date received is greater than or equal to 2025-10-24, then Q233 “Were molecular tests for molecular markers performed?” must be answered	Q33-Q40 and Q233-Q240 will be disabled as molecular markers at diagnosis and last evaluation are now collected on F2402 r10 when primary disease is MPN Molecular markers at last evaluation will still be collected on F2057 when the primary disease on F2402 is AML but a transformation has been reported
2058 r2	Q61	Validation (Modify)	Q61 “Direct bilirubin” must be answered	If date received is less than or equal to 2025-10-24 then Q61 “Direct bilirubin” must be answered	Q61-Q63 will be disabled as direct bilirubin is now collected on F2402 r10
2012 r3	Q253 & Q256	Validation (Modify)	Q253 “What was the disease status?” must be answered Q256 “Date assessed” must be answered	If date received is less than or equal to 2025-10-24, then Q253 “What was the disease status?” must be answered If date received is less than or equal to 2025-10-24, then Q256 “Date assessed” must be answered	Q253-Q256 will be disabled as CML disease status is now collected on F2402 r10
2016 r5	Q3, Q5 & Q7	Validation (Modify)	If and only if “Is this the report of a second or subsequent transplant or cellular therapy for the same disease?” is equal to “no,” then Q3 “Hemoglobin” must be answered If and only if “Is this the report of a second or subsequent transplant or cellular therapy for the same disease?” is equal to “no,” then Q5 “Serum calcium” must be answered If and only if “Is this the report of a second or subsequent transplant or cellular therapy for the same disease?” is equal to “no,” then Q7 “Serum creatinine” must be answered	If and only if “Is this the report of a second or subsequent transplant or cellular therapy for the same disease?” is equal to “no” and date received is less than or equal to 2025-10-24, then Q3 “Hemoglobin” must be answered If and only if “Is this the report of a second or subsequent transplant or cellular therapy for the same disease?” is equal to “no” and date received is less than or equal to 2025-10-24, then Q5 “Serum calcium” must be answered If and only if “Is this the report of a second or subsequent transplant or cellular therapy for the same disease?” is equal to “no” and date received is less than or equal to 2025-10-24, then Q7 “Serum creatinine” must be answered	Q3-Q9 will be disabled as lab values are now collected on F2402 r10
	Q234	Validation (Modify)	Q234 “Were cytogenetics tested?” must be answered	If and only if “Is this the report of a second or subsequent transplant or cellular therapy for the same disease?” is equal to “no,” then Q234 “Were cytogenetics tested?” must be answered	Q234-Q236 will be disabled as cytogenetics for subsequent infusions for MM/PCD will now be collected on F2402 r10
2026 r2	Q179, Q213, Q249	Validation (Add)		If date received is greater than or equal to 2025-10-24, then Q179 “Specify the best response to chemotherapy” must not be equal to “very good partial response” or “minimal response” or “not evaluable” If date received is greater than or equal to 2025-10-24, then Q213 “Best response to line of therapy” must not be equal to “very good partial response” or “minimal response” or “not evaluable” If date received is greater than or equal to 2025-10-24, then Q249 “Specify the disease status immediately prior to the preparative regimen” must not be equal to “very good partial response” or “minimal response” or “not evaluable”	Disease response options for neuroblastoma have been added to F2402 r10 and new validations/custom error messages will keep disease status consistent until neuroblastoma forms are updated
2126 r2	Q1	Validation (Add)		If date received is greater than or equal to 2025-10-24, then Q1 “Best response” must not be equal to “very good partial response” or “minimal response” or “not evaluable”

September 2025 (Released September 26th, 2025)

Form Revision	Question	Type of Change	Current	New	Rationale for Change
F2402 r9	Q416	Modify	Radios button for answer options (single answer)	Check all that apply	Recent form revisions removed the combined light and heavy chain deposition disease option, but since patients may have both, answer fields will now be ‘check all that apply’
F2116 r5		Validation (modify)	If Q1 is equal to any (MM, MM_LT_CH, MM_NONSEC, PCL, SOL_PLASMA, SM, OSTEOSCL_POEMS, MGRS, OTH_PCL), then Q3 must be answered. If Q142 = yes AND Q1 is equal to any (MM, MM_LT_CH, MM_NONSEC, PCL, SOL_PLASMA, SM, OSTEOSCL_POEMS, MGRS, OTH_PCL) then Q163 must be answered. If Q1 is equal to any (MM, MM_LT_CH, MM_NONSEC, PCL, SOL_PLASMA, SM, OSTEOSCL_POEMS, MGRS, OTH_PCL), then Q251 must be answered	If Q1 is equal to any (MM, MM_LT_CH, MM_NONSEC, PCL, SOL_PLASMA, SM, OSTEOSCL_POEMS, OTH_PCL), then Q3 must be answered. If Q142 = yes AND Q1 is equal to any (MM, MM_LT_CH, MM_NONSEC, PCL, SOL_PLASMA, SM, OSTEOSCL_POEMS, OTH_PCL), then Q163 must be answered. If Q1 is equal to any (MM, MM_LT_CH, MM_NONSEC, PCL, SOL_PLASMA, SM, OSTEOSCL_POEMS, OTH_PCL), then Q251 must be answered	The validations have been updated to remove MGRS, since there is not disease response criteria

August 2025 (Released August 22nd, 2025)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2402 r4-9		Validation (Modify)	If and only if “What was the primary disease for which the HCT / cellular therapy was performed?” is equal to “Histiocytic Disorders” and “Did the recipient have an active or recent infection with a viral pathogen?” is equal to “no,” then “Has the recipient ever been infected with PCP / PJP?” must be answered	If and only if “What was the primary disease for which the HCT / cellular therapy was performed?” is equal to “Histiocytic Disorders” then “Has the recipient ever been infected with PCP / PJP?” must be answered	PCP / PJP should be reported for all patients with Histiocytic Disorders
F2400 r6-10		Validation (Add)		If “NMDP facilitated” is not equal to “yes,” then “Registry” must not be equal to “U1CB” or “USA1”	Validation added to ensure correct registry or cord bank is reported
F2044 r2	Q82 & Q115	Validation (Modify)	Q82 (Date of evaluation prior to mobilization for stem cell collection) must be less than or equal to date of HSCT for which this form is being completed minus 120 days Q115 (Date CBC tested) must be less than or equal to date of HSCT for which this form is being completed minus 120 days	Q82 (Date of evaluation prior to mobilization for stem cell collection) must be greater than or equal to date of HSCT for which this form is being completed minus 120 days Q115 (Date CBC tested) must be greater than or equal to date of HSCT for which this form is being completed minus 120 days	Validation was incorrect and has been updated to match instructions on the form

Additional Note: Question numbers were added in front of Donor ID field to every row in table that collects the percent of donor cells for each type of cells that were tested on F2451 r3

July 2025 (Released July 25th, 2025)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2100 r9	Q57	Floating Text (Add)		After “yes” option in Q57 (Were studies on chimerism performed?), add instructional text “Also complete Chimerism Essential Data Form 2451”	Chimerism data will be collected on F2451 after form is released
		Validation (Modify)	If and only if Q57 (Were studies on chimerism performed?) is equal to “yes,” then Q58-74 must be answered	If and only if Q57 (Were studies on chimerism performed?) is equal to “yes” and date received is less than or equal to 2025-07-25, then Q58-74 must be answered
		Events and Actions (Modify)		If date received is greater than or equal to 2025-07-25 and Q57 (Were studies on chimerism performed?) is equal to “yes,” then F2451 will come due
F2400 r10	Q79	Validation (Modify)	If and only if Q44 (Specify donor) is equal to “autologous” and Q47 (Is product genetically modified?) is equal to “yes,” then Q79 (Name of product) must be answered	If and only if infusion type is equal to gene therapy, then Q79 (Name of product) must be answered	Field should not be enabled for genetically modified HCTs

June 2025 (Released June 27th, 2025)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2014 r4	Q5	Validation (Modify)	Date of diagnosis of prior disease must be between F2402 Q1 date of diagnosis of primary disease for HCT / Cellular Therapy and F2400 Q1 date of birth	Date of diagnosis of prior disease must be between F2400 Q1 date of birth and F2402 Q1 date of diagnosis of primary disease for HCT / Cellular Therapy	The order of the fields in the validation was preventing the validation from working correctly

May 2025 (Released May 16, 2025)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2010 r4	Q56	Floating Text (Delete)	Floating text next to answer options for Complete remission (CR), Complete Remission with incomplete hematologic recovery (CRi)	Floating text removed	Updated to align with Forms Instruction Manual
F2400 r10	Q12	Validation (Modify)	Standard validation error message	Custom Error Message: This question should only be answered for the recipient’s first allogeneic transplant. If the recipient has had prior autologous or cellular therapy infusions, and this infusion is the first allogeneic, please override the error message. If the recipient has had prior allogeneic infusion(s), please leave this question blank.	Data quality improvement

April 2025 (Released April 18, 2025)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2100 r9		Validation (Delete)	A validation exists within the organ impairment section that states if the visit is 100D, previously reported cannot be answered	Validation removed	The organ impairment section was recently revised and centers are instructed to report previously reported if the impairment was diagnosed prior to the infusion and persisted into the follow-up reporting period
F2013 r4	Q105	Validation (Modify)	Q105 Did the recipient have known nodal involvement? Must be answered	Updated validation to disable last evaluation section when CLL transformed to NHL	Questions are no longer applicable since the disease transformed
F2003 r2	Q11-15	Floating Text (Add)		Q11-15 will now allow multiple instances for reporting multiple mobilizations of the product	Reduce form burden for these commercial products
F2100 r9 and F4100 r9		Validation (Modify)		Improvements to the functionality of several validations using the recipient’s age on the date of contact (ex. height/weight, pregnancy)	Updating the questions to use new interactive disabling functionality so the validations work correctly with the contact date
F2450 r8		Validation (Add)		Adding a rule: date of diagnosis of chronic GVHD must be after date of diagnosis of acute GVHD	Consistency amongst forms (similar validation exists on the 2100)

March 2025 (Released March 28, 2025)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2402 r9	Q503	Validation (add)	There is no validation for Q503 currently	If and only if Q513 (Specify histiocytic disorder classification) = Other pigmentary dilution disorder, then Q503 (Specify other pigmentary dilution disorder) must be answered	Q503 should be answered if “Other pigmentary dilution disorder” is selected in Q513

February 2025 (released February 21, 2025)

F2157 r1 Q281-284: When option value of “none” was selected on Q281 & Q283, date assessed Q282 & Q284 were not enabling. Corrections were made so questions would enable correctly.

January 2025 (released January 24, 2025)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2130 r4	Q66	Validation (Modify)	If and only if F2402 Q492 is equal to no, then Q66 must be answered	If and only if visit is equal to any (100D, 6M, 1Y, 2Y), then Q66 must be answered	Updated to align with Forms Instruction Manual
F2402 r9	Q425	Floating Text (Modify)	Instructional text above Q425: “Labs at diagnosis, or if subsequent infusion, report based on last relapse / progression prior to this infusion”	Instructional text above Q425: “Labs at diagnosis”	Updated to align with Forms Instruction Manual
	Q429		Instructional text above Q429: “I.S.S. at diagnosis, or if subsequent infusion, report based on last relapse / progression prior to this infusion”	Instructional text above Q429: “I.S.S. at diagnosis”
	Q431		Instructional text above Q431: “R-I.S.S. at diagnosis, or if subsequent infusion, report based on last relapse / progression prior to this infusion”	Instructional text above Q431: “R-I.S.S. at diagnosis”
	Q433		Instructional text above Q433: “Labs at diagnosis, or if subsequent infusion, report based on last relapse / progression prior to this infusion”	Instructional text above Q433: “Labs at diagnosis, or if subsequent infusion, report based on last evaluation prior to the start of the preparative regimen / infusion”
	Q441		Instructional text above Q441: “Labs at diagnosis, or if subsequent infusion, report based on last relapse / progression prior to this infusion”	Instructional text above Q441: “Labs at diagnosis”
			Floating text within Q441: “at diagnosis, or if subsequent infusion, report based on last relapse / progression prior to this infusion”	Floating text within Q441: “at diagnosis”

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.